Company Name : Taro Pharmaceutical Industries Ltd.

Thursday, May 23, 2019 11:00AM IST (5:30AM GMT)
Taro Provides Results for the Year Ended March 31, 2019
HAWTHORNE, N.Y., United States

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2019.

 

Quarter ended March 31, 2019 Highlights ─ compared to March 31, 2018

 
  • Net sales of $179.9 million increased $4.7 million, mainly driven by a 4.1% increase in overall volumes.
  • Gross profit of $119.5 million (66.4% of net sales compared to 67.9%) increased $0.6 million.
  • Research and development (R&D) expenses of $20.5 million remained in line with prior year.
  • Selling, marketing, general and administrative expenses (SG&A) of $23.3 million decreased $0.5 million.
  • Operating income of $75.4 million (41.9% of net sales compared to 42.7%) increased $0.6 million.
  • Interest and other financial income increased $2.3 million to $8.2 million.
  • Foreign Exchange (FX) expense of $9.4 million compared to income of $16.0 million - an unfavorable impact of $25.4 million, principally the result of the weakening of the U.S. dollar vs. the Canadian dollar. The FX impact is mainly balance sheet driven.
  • Tax expense of $15.6 million increased $5.0 million; with the effective tax rate of 21.1% compared to 11.0%.
  • Net income attributable to Taro was $58.4 million compared to $86.3 million, a $27.9 million decrease, resulting in diluted earnings per share of $1.52 compared to $2.17.
     

Year ended March 31, 2019 Highlights ─ compared to March 31, 2018

 
  • Net sales of $669.9 million increased $8.0 million, mainly driven by a 7.5% increase in overall volumes.
  • Gross profit of $445.7 million (66.5% of net sales compared to 70.0%) decreased $17.8 million.
  • R&D expenses of $63.2 million decreased $7.2 million, principally due to the continuous evaluation of our portfolio and adjusting for viable development of products.
  • SG&A of $90.0 million increased $1.8 million.
  • Operating income of $296.2 million (44.2% of net sales compared to 45.8%) decreased $6.8 million.
  • Interest and other financial income increased $13.6 million to $33.5 million.
  • FX income of $25.3 million compared to FX expense of $32.5 million - a favorable impact of $57.8 million, principally the result of the strengthening of the U.S. dollar vs. the Canadian dollar. The FX impact is mainly balance sheet driven.
  • Tax expense of $74.7 million decreased $7.2 million; with the effective tax rate of 20.9% compared to 28.0%. During the third quarter of 2018, the Company recorded a $38.0 million expense for the impact of the re-measurement of the Company's estimated net deferred tax asset, as a result of the Tax Cuts and Jobs Act. Excluding the impact from the one-time re-measurement, the tax expense would have been $44.0 million with an effective tax rate of 15.0%.
  • Net income attributable to Taro was $281.8 million compared to $211.2 million, a $70.6 million increase, resulting in diluted earnings per share of $7.23 compared to $5.26. Excluding the impact of the one-time tax re-measurement, prior year net income attributable to Taro would have been $248.0 million, or diluted earnings per share of $6.18.
     

Cash Flow and Balance Sheet Highlights

 
  • Cash flow provided by operations for the year ended March 31, 2019 was $323.7, similar to the year ended March 31, 2018.
  • As of March 31, 2019, cash, including short-term bank deposits and marketable securities (both short and long-term) decreased $294.6 million to $1.4 billion from March 31, 2018. The decrease reflects the impact from the $500.0 million special dividend paid in December 2018 and the $88.8 million impact from the completion of the Company’s share repurchase program.
     

Mr. Uday Baldota, Taro’s CEO stated, “Despite the challenging market conditions we face due primarily to the continuing pricing pressure, our team has delivered a good performance. With a clearly defined strategy, we are shaping our business and product portfolio with internal and inorganic developments. This effort is aimed at doing more for patients and staying relevant for our customers.”

 

FDA Approvals and Filings

 

The Company recently received approvals from the U.S. Food and Drug Administration (“FDA”) for five Abbreviated New Drug Applications (“ANDAs”): Minoxidil Topical Aerosol, 5% (for women); Clobazam Oral Suspension, 2.5 mg/mL; Naftifine Hydrochloride Gel USP, 2%; Dapsone Tablets USP, 25 mg and 100 mg and Deferiprone Tablets 500mg. The Company currently has a total of twenty-six ANDAs awaiting FDA approval, including eight tentative approvals.

 

Earnings Call(8:00 am ET, May 23, 2019)

 

As previously announced, the Company will host an earnings call at 8:00 am ET on Thursday, May 23, 2019, where senior management will discuss the Company’s performance and answer questions from participants. This call will be accessible through an audio dial-in and a web-cast. Audio conference participants can dial-in on the numbers below:

 
  • Participant Toll-Free Dial-In Number: +1 (844) 421-0601 ID: 8698095
  • Participant International Dial-In Number: +1 (716) 247-5800 ID: 8698095
  • Web-cast: More details are provided on our website, www.taro.com
     

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available on the Company’s website at www.taro.com. An audio playback will be available for ten (10) days following the call.

 

The Company cautions that the foregoing financial information is unaudited and could be subject to change.

 

************************

 

About Taro

 

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

 

SAFE HARBOR STATEMENT

 

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company.The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

 

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2019.Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained.Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F.Forward-looking statements are applicable only as of the date on which they are made.The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

 

**Financial Tables Follow**

 
                   
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except share data)

                   
        Quarter Ended   Year Ended
        March 31,   March 31,
       

2019

 

2018

 

2019

 

2018

        (unaudited)   (unaudited)   (unaudited)   (audited)
Sales, net       $ 179,921     $ 175,216     $ 669,893     $ 661,913  
Cost of sales         60,384       56,287       224,169       198,405  
Gross profit         119,537       118,929       445,724       463,508  
                     
Operating Expenses:                    
Research and development         20,512       20,308       63,238       70,418  
Selling, marketing, general and administrative         23,321       23,775       89,971       88,196  
Settlements and loss contingencies         322       24       (3,678)       1,884  
Operating income         75,382       74,822       296,193       303,010  
                     
Financial (income) expense, net:                    
Interest and other financial income         (8,241)       (5,894)       (33,542)       (19,934)  
Foreign exchange expense (income)         9,397       (16,041)       (25,309)       32,465  
Other (loss) gain, net         (100)       458       1,810       1,889  
Income before income taxes         74,126       97,215       356,854       292,368  
Tax expense         15,649       10,691       74,732       81,954  
Income from continuing operations         58,477       86,524       282,122       210,414  
Net loss from discontinued operations attributable to Taro               (96)             (335)  
Net income         58,477       86,428       282,122       210,079  
Net income (loss) attributable to non-controlling interest         42       141       345       (1,071)  
Net income attributable to Taro       $ 58,435     $ 86,287     $ 281,777     $ 211,150  
                     
Net income per ordinary share from continuing operations attributable to Taro:          
Basic and Diluted       $ 1.52     $ 2.17       $ 7.23     $ 5.27  
                     
Net loss per ordinary share from discontinued operations attributable to Taro:          
Basic and Diluted      

$

    $ (0.00)   *

  $

    $ (0.01)  
                     
Net income per ordinary share attributable to Taro:                    
Basic and Diluted       $ 1.52     $ 2.17       $ 7.23     $ 5.26  
                     
Weighted-average number of shares used to compute net income per share:          
Basic and Diluted         38,548,516       39,729,942       38,990,058       40,155,087  
                     
* Amount is less than $0.01                    
May not foot due to rounding.                    
                     
             
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
             
        March 31,   March 31,
        2019   2018
ASSETS       (unaudited)   (audited)
CURRENT ASSETS:            
Cash and cash equivalents       $ 567,451   $ 576,611
Short-term and current maturities of long-term bank deposits             296,188
Marketable securities         481,883     549,821
Accounts receivable and other:            
Trade, net         237,945     206,455
Corporate tax receivable         25,969     100,380
Other receivables and prepaid expenses         21,393     22,585
Inventories         148,079     144,595
TOTAL CURRENT ASSETS         1,482,720     1,896,635
Long-term deposits and marketable securities         304,322     225,639
Property, plant and equipment, net         206,242     193,727
Deferred income taxes         110,974     87,257
Other assets         31,068     29,952
TOTAL ASSETS       $ 2,135,326   $ 2,433,210
             
LIABILITIES AND SHAREHOLDERS' EQUITY            
CURRENT LIABILITIES:            
Trade payables       $ 35,060   $ 25,697
Other current liabilities         181,761     190,059
TOTAL CURRENT LIABILITIES         216,821     215,756
Deferred taxes and other long-term liabilities         7,383     7,055
TOTAL LIABILITIES         224,204     222,811
             
Taro shareholders' equity         1,905,536     2,205,158
Non-controlling interest         5,586     5,241
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY       $ 2,135,326   $ 2,433,210
                 
         
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENT OF CASH FLOWS
(U.S. dollars in thousands)
         
        Year Ended March 31,
        2019   2018
        (unaudited)   (audited)
Cash flows from operating activities:            
Net income       $ 282,122     $ 210,079  
Adjustments required to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization         18,597       16,496  
Realized loss on sale of marketable securities and long-lived assets         27       275  
Change in derivative instruments, net         3,115       (893)  
Effect of change in exchange rate on inter-company balances, marketable securities and bank deposits         (29,533)       34,970  
Deferred income taxes, net         12,262       56,007  
Increase in trade receivables, net         (32,088)       (2,297)  
Increase in inventories, net         (5,515)       (1,978)  
Decrease in other receivables, income tax receivable, prepaid expenses and other         74,256       12,644  
Increase (decrease) in trade, income tax, accrued expenses, and other payables         529       (936)  
Income from marketable securities, net         (63)       (678)  
Net cash provided by operating activities         323,709       323,689  
             
Cash flows from investing activities:            
Purchase of plant, property & equipment, net         (27,018)       (26,886)  
Investment in other intangible assets         (3,666)       (2,650)  
Proceeds from short-term bank deposits, net         225,503       161,032  
Proceeds from long-term deposits and other assets         70,685       396,281  
Investment in marketable securities, net         (8,368)       (770,490)  
Proceeds from the sale of long-lived assets               1,075  
Net cash provided by (used in) investing activities         257,136       (241,638)  
             
Cash flows from financing activities:            
Purchase of treasury stock         (88,849)       (106,986)  
Dividends paid         (500,000)        
Net cash used in financing activities         (588,849)       (106,986)  
             
Effect of exchange rate changes on cash and cash equivalents         (1,156)       1,147  
Decrease in cash and cash equivalents         (9,160)       (23,788)  
Cash and cash equivalents at beginning of period         576,611       600,399  
Cash and cash equivalents at end of period       $ 567,451     $ 576,611  
             
Cash Paid during the year for:            
Income taxes       $ 71,096     $ 55,051  
Cash Received during the year for:            
Income taxes       $ 69,436     $ 36,668  
Non-cash investing transactions:            
Purchase of property, plant and equipment included in accounts payable       $ 4,740     $ 2,281  
Non-cash financing transactions:            
Purchase of treasury stock       $     $ 4,348  
Purchase of marketable securities       $ 2,003     $ 3,491  

 

 

 

Source: BUSINESS WIRE INDIA

Click here for Media Contact Details
CONTACTS :

Mariano Balaguer
VP, Chief Financial Officer
(914) 345-9001
Mariano.Balaguer@Taro.com

William J. Coote
AVP, Business Finance, Treasurer and Investor Relations
(914) 345-9001
William.Coote@Taro.com


More News from Taro Pharmaceutical Industries Ltd.

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2019

22/06/2019 4:31PM

Taro Pharmaceutical Industries Ltd. (NYSE: TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2019, filed with the Securities and Exchange Commission (the ...

Taro to Announce Full Year Results on May 22, 2019

17/05/2019 11:05AM

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced that it plans to release its financial results for year ended March 31, 2019, on Wednesday, May 22, 2019.   The Company will conduct an earnings call ...

Taro Provides Results for December 31, 2018

07/02/2019 12:08PM

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2018.   Quarter ...


Similar News

TAC Security Founder Trishneet Arora Features in Fortune India’s 40 Under 40 List

26/06/2019 4:45PM

At the young age of just 25, Trishneet Arora makes his way to the prestigious Fortune India’s 40 Under 40 List, a list of individuals that the publication considers to be “India’s Brightest Business ...

Tech Giant Alibaba Cloud Partners With UAE’s Group 42 to Host First MEA Internet Summit

26/06/2019 3:10PM

Alibaba Cloud, the data intelligence backbone of Alibaba Group, today held its inaugural Middle East and Africa (MEA) Internet Summit in partnership with UAE-based Artificial Intelligence (AI) and Cloud Computing leader ...